A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer.
Morgensztern
Daniel
D
Perry
Michael C
MC
Govindan
Ramaswamy
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D000077143:Docetaxel; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage; D019772:Topotecan / Q000008:administration & dosage; D017211:Treatment Failure
D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D019772:Topotecan; D000069585:Filgrastim